Table 1:
US FDA-approved monoclonal antibody for cancer treatment.
| Target | mAb name | 1st approval year | Format | Application |
|---|---|---|---|---|
| CD20 | Rituximab | 1997 | Chimeric IgG1 | Non-Hodgkin lymphoma |
| Ofatumumab | 2009 | Human IgG1 | Chronic lymphocytic leukemia | |
| Obinutuzumab | 2013 | Humanized IgG1 | Chronic lymphocytic leukemia | |
| HER2 | Trastuzumab | 1998 | Humanized IgG1 | Breast cancer |
| Pertuzumab | 2012 | Humanized IgG1 | Breast cancer | |
| EGFR | Cetuximab | 2004 | Chimeric IgG1 | Colorectal cancer |
| Necitumumab | 2015 | Human IgG1 | NSCLC | |
| Panitumumab | 2006 | Human IgG2 | Colorectal cancer | |
| PD-1 | Cemiplimab | 2018 | Human mAb | Cutaneous squamous cell carcinoma |
| Nivolumab | 2014 | Human IgG4 | Melanoma, NSCLC | |
| Pembrolizumab | 2014 | Human IgG4 | Melanoma | |
| CTLA-4 | Ipilimumab | 2011 | Human IgG1 | Metastatic melanoma |
| PD-L1 | Atezolizumab | 2016 | Humanized IgG1 | Bladder cancer |
| Avelumab | 2017 | Human IgG1 | Merkel cell carcinoma | |
| Durvalumab | 2017 | Human IgG1 | Bladder cancer | |
| SLAMF7 | Elotuzumab | 2014 | Humanized IgG1 | Multiple myeloma |
| CD38 | Daratumumab | 2015 | Human IgG1 | Multiple myeloma |
| Isatuximab | 2021 | Chimeric IgG1 | Multiple myeloma | |
| CD52 | Alemtuzumab | 2001 | Humanized IgG1 | Chronic myeloid leukemia |
| VEGF-A | Bevacizumab | 2004 | Humanized IgG1 | Colorectal cancer |
| VEGFR2 | Ramucirumab | 2014 | Human IgG1 | Gastric cancer |
| CD19 | Tafasitamab | 2020 | Humanized IgG1 | Diffuse large B-cell lymphoma |
| LAG-3 | Relatlimab | 2022 | Human IgG4 | Melanoma |
EGFR, epidermal growth factor receptor; HER2, epidermal growth factor receptor 2; PD-L1, programmed cell death 1 ligand 1; FDA, Food and Drug Administration.